• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

    12/1/23 6:26:32 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DO CUONG V

    (Last) (First) (Middle)
    C/O BIOVIE INC.
    680 W NYE LANE STE 201

    (Street)
    CARSON CITY NV 89703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIOVIE INC. [ BIVI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    11/30/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock 11/30/2023 P 10,000 A $1.78 68,759 D
    Common Stock 425,854 I See Footnote(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Securities are held in the name of Do & Rickles Investments LLC.
    /s/ Cuong V Do 12/01/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIVI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Inc. Announces Closing of $12 Million Public Offering

    CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI, BIVIW)), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the "Warrants") (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant ("Pre-Funded Warrants") and one Warrant). Each unit was sold to the public at a price of $2.00 per unit (and

    8/11/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Inc. Announces Pricing of $12 Million Public Offering

    CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI, BIVIW)), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the "Warrants") (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the "Pre-Funded Warrants") and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-fun

    8/7/25 8:43:10 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Rogich Sigmund was granted 32,700 shares, increasing direct ownership by 774% to 36,926 units (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    1/7/25 5:26:37 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berman Richard J was granted 34,200 shares, increasing direct ownership by 531% to 40,643 units (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    1/7/25 5:24:53 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Do Cuong V bought 5,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    8/13/25 4:05:17 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Do Cuong V bought 10,000 shares (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    3/6/24 5:12:41 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Do Cuong V bought $17,800 worth of shares (10,000 units at $1.78), increasing direct ownership by 17% to 68,759 units (SEC Form 4)

    4 - BIOVIE INC. (0001580149) (Issuer)

    12/1/23 6:26:32 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    SEC Filings

    View All

    SEC Form 10-K filed by BioVie Inc.

    10-K - BIOVIE INC. (0001580149) (Filer)

    8/15/25 5:05:22 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIOVIE INC. (0001580149) (Filer)

    8/11/25 4:25:18 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by BioVie Inc.

    424B5 - BIOVIE INC. (0001580149) (Filer)

    8/8/25 5:09:59 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

    Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00

    7/22/22 7:51:28 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities reiterated coverage on BioVie with a new price target

    B. Riley Securities reiterated coverage of BioVie with a rating of Buy and set a new price target of $27.00 from $50.00 previously

    11/30/21 8:23:48 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Financials

    Live finance-specific insights

    View All

    BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

    CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes, held August 10–13 in Santa Fe, New Mexico.   Long COVID is now recognized as a leading neurological condition that has affected an estimated 400 million individuals worldwide,1,2 .The Centers for Disease Control has reported that 6.9% of adults in the United St

    8/13/25 4:05:00 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

    CARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Decreases Biological Age Acceleration in Alzheimer's Disease" at the 2nd World Conference on Aging and Gerentology (WCAG-2025) in Rome, Italy July 14-15, 2025. As the body ages, a natural process called DNA methylation occurs and adds "methyl" groups to the surface of DNA. Accumulated methylation has the impact of interfering with how DNA is decoded and thus has been shown to impact a wide range of dis

    7/24/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

    CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented "Bezisterim Epigenetic Effects on Aging and Neurodegeneration" at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer's Disease (AD) treatment that focuses on changing one gene product (e.g., amyloid, p-Tau) at a time, bezisterim modulates inflammation and is believed to help reestablish homeostasis and small changes in

    7/9/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by BioVie Inc.

    SC 13G - BIOVIE INC. (0001580149) (Subject)

    10/25/24 4:01:25 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BioVie Inc.

    SC 13D/A - BIOVIE INC. (0001580149) (Subject)

    6/25/24 7:47:33 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by BioVie Inc. (Amendment)

    SC 13D/A - BIOVIE INC. (0001580149) (Subject)

    3/10/23 5:15:43 PM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIVI
    Leadership Updates

    Live Leadership Updates

    View All

    BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

    The seven-member Board includes Cedars-Sinai brain health leader Dr. Zaldy Tan, Parkwood marketing powerhouse Justina Omokhua, and Neuralink visionary Tim Gardner Each Board member brings deep personal conviction and cross-sector expertise to unlock value and reshape care in Alzheimer's, Parkinson's and other neuroinflammatory disorders CARSON CITY, Nev., May 05, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of its Corporate Advisory Board – a coalition of seven powerhous

    5/5/25 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

    CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

    6/4/24 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioVie Announces the Appointment of a New Chief Medical Officer

    RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

    11/1/21 8:00:00 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care